Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a report published on Wednesday morning.

Other analysts have also recently issued reports about the stock. HC Wainwright dropped their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, August 6th. B. Riley lowered shares of Actinium Pharmaceuticals from a buy rating to a neutral rating and dropped their price objective for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, Maxim Group cut their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating on the stock in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $11.40.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $1.80 on Wednesday. The company has a 50-day moving average price of $3.69. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24. The company has a market capitalization of $53.61 million, a price-to-earnings ratio of -1.05 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. On average, equities analysts anticipate that Actinium Pharmaceuticals will post -1.38 EPS for the current year.

Institutional Trading of Actinium Pharmaceuticals

Large investors have recently modified their holdings of the company. Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals during the 1st quarter valued at about $78,000. Vanguard Group Inc. raised its holdings in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after buying an additional 82,113 shares during the last quarter. Virtu Financial LLC boosted its position in shares of Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after buying an additional 62,459 shares during the period. Bank of New York Mellon Corp grew its holdings in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Actinium Pharmaceuticals by 23.4% in the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after acquiring an additional 7,525 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.